Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2005

View Archived Issues

P-selectin inhibitor from Wyeth effective in models of vascular inflammation and atherosclerosis

Similar PK parameters reported for two oral formulations of rizatriptan in healthy subjects

Central effects of cannabinoids

NK1 receptor antagonism elicits antitumor activity

New data on the pharmacokinetics and pharmacodynamics of dabigatran

Update on the effects and safety of INS-50589

Phase II data on rhThrombin in the management of postoperative bleeding

Active second quarter at Schering-Plough

Meda to acquire Viatris

RegeneRx collaborates with Children's National Medical Center for TB4

Samaritan establishes Samaritan Europe

Teva receives follow-up approvable letter for Agilect

Acambis and VIB team up on flu vaccine development

ODAC schedules reviews for September meeting

European MRP completed for Remodulin

ChondroGene forms alliance with UCSF

FDA explains clinical hold of phase II study of arimoclomol for ALS

Orthokine shows efficacy for osteoarthritis

ChemGenex receives grants for diabetes research

Corautus Genetics signs agreements for VEGF-2 for diabetic neuropathy

AnGes and Avontec sign crosslicense agreement

Positive outcomes from phase III study of regadenoson for MPI

FDA approval for Fortical

New therapeutics for cancer disclosed in recent patent literature

Recent patents reveal novel agents for respiratory diseases

Therapeutic agents for arthritis and other musculoskeletal diseases prepared and tested